[en] Czech has put their priority in developing the radiopharmaceuticals based on reactor produced Ho-166 and a related fabrication will be extended to other EU conturies including Germany, France, etc after a development of project. The collaboration will be based on the mutual agreement for developing the between research institutes, industries and academic institutes and further researches should be followed by the issue of developing radiopharmaceuticals using Ho-166. To strengthen the collaboration, detailed discussions for the practical collaboration have been made through the visitation to the research institution of each counter part. For implementing the collaboration between NPI and KAERI, an institutional basis technical cooperation agreement(TCA) will be concluded. Furthermore, agreement for the substantial collaboration on Ho-166 related researches will be made after the conclusion of the TCA. It will accelerate the commercialization of KAERI developed Ho-166 therapeutic agents into other European countries once authorization is acquired in Czech because the regulatory authorization for the approval as a commercialization of radiopharmaceuticals in Czech is very similar to other EU countries. Thereby, its commercialization of Ho-166 products in Czech will lead to potential commercialization on other EU countries and this would be returning to KAERI in the from of investment profits. It is certain that the technical exportation of Ho-166 based therapeutic agents that have been developed KAERI into European countries such as France and Germany, etc. will be ensured through the successful technical collaboration program between KAERI and NPI